Similar to the first quarter, growth of our Pharma segment was driven by strong demand for elastomeric components for injectable drugs and exit Material Solutions, which offset declines in sales to the prescription and consumer healthcare markets, which continue to be impacted by customers drawing down inventory levels in key categories.
Aptar's adjusted EBITDA increased 8% to $148 million compared to the prior year, and this included the negative impact of the shift in business across our markets as well as a net negative inflation impact of approximately $9 million.
Our consolidated adjusted EBITDA margin would have been approximately 180 basis points higher without the net negative inflation effect and the margin compression impact from passing on the higher costs.
In our Food + Beverage segment, top line growth was strong across each market segment with about 60% of the growth coming from price adjustments related to the passing through of higher resin costs.
Our Beauty + Home segment reported solid growth in the beauty and home care markets, the former being mostly on easier comparison to the depressed second quarter of 2020 although with some initial signs of recovery.
In Consumer Healthcare, our pressure-free ophthalmic squeeze dispenser is the delivery device for a new over-the-counter iLubricant by Bausch and Lomb Biotrue brand in the U.S. In Beauty + Home, we recently announced a strategic sustainable dispensing system, our first fully recyclable non-material dispenser pump for the beauty and personal care products called Future.
Second quarter adjusted earnings per share increased 7% to $0.91 per share on a comparable basis with the prior year and when neutralizing currency effects.